Peripheral Embolic Protection Devices - Medical Devices Pipeline Assessment, 2017
Summary
GlobalData's Medical Devices sector report, “Peripheral Embolic Protection Devices - Medical Devices Pipeline Assessment, 2017" provides an overview of Peripheral Embolic Protection Devices currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Peripheral Embolic Protection Devices pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Peripheral Embolic Protection Devices under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Peripheral Embolic Protection Devices and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Peripheral Embolic Protection Devices under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Peripheral Embolic Protection Devices Overview 7
3 Products under Development 8
3.1 Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development 8
3.2 Peripheral Embolic Protection Devices - Pipeline Products by Segment 9
3.3 Peripheral Embolic Protection Devices - Pipeline Products by Territory 10
3.4 Peripheral Embolic Protection Devices - Pipeline Products by Regulatory Path 11
3.5 Peripheral Embolic Protection Devices - Pipeline Products by Estimated Approval Date 12
3.6 Peripheral Embolic Protection Devices - Ongoing Clinical Trials 13
4 Peripheral Embolic Protection Devices - Pipeline Products under Development by Companies 14
4.1 Peripheral Embolic Protection Devices Companies - Pipeline Products by Stage of Development 14
4.2 Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development 15
5 Peripheral Embolic Protection Devices Companies and Product Overview 16
5.1 Abbott Vascular Inc Company Overview 16
5.1.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 16
5.2 Avantec Vascular Corporation Company Overview 17
5.2.1 Avantec Vascular Corporation Pipeline Products & Ongoing Clinical Trials Overview 17
5.3 BTG Plc Company Overview 18
5.3.1 BTG Plc Pipeline Products & Ongoing Clinical Trials Overview 18
5.4 Cardio-Flow Ltd. Company Overview 22
5.4.1 Cardio-Flow Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
5.5 CardioGard Ltd. Company Overview 23
5.5.1 CardioGard Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23
5.6 EMBA Medical Limited Company Overview 26
5.6.1 EMBA Medical Limited Pipeline Products & Ongoing Clinical Trials Overview 26
5.7 Emboline, Inc. Company Overview 27
5.7.1 Emboline, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
5.8 Filterlex Medical Ltd Company Overview 28
5.8.1 Filterlex Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
5.9 Inari Medical, Inc. Company Overview 29
5.9.1 Inari Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
5.10 Innovative Cardiovascular Solutions, LLC Company Overview 32
5.10.1 Innovative Cardiovascular Solutions, LLC Pipeline Products & Ongoing Clinical Trials Overview 32
5.11 Innovia LLC Company Overview 35
5.11.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 35
5.12 Keystone Heart Ltd Company Overview 36
5.12.1 Keystone Heart Ltd Pipeline Products & Ongoing Clinical Trials Overview 36
5.13 Medtronic plc Company Overview 39
5.13.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 39
5.14 Metactive Medical LLC Company Overview 40
5.14.1 Metactive Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 40
5.15 MIV Therapeutics Inc Company Overview 41
5.15.1 MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 41
5.16 Neurosonix Ltd. Company Overview 42
5.16.1 Neurosonix Ltd. Pipeline Products & Ongoing Clinical Trials Overview 42
5.17 Shape Memory Therapeutics, Inc. Company Overview 43
5.17.1 Shape Memory Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
5.18 Trinity College Dublin Company Overview 44
5.18.1 Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 44
5.19 University of Minnesota Company Overview 45
5.19.1 University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview 45
5.20 University of Toledo Company Overview 46
5.20.1 University of Toledo Pipeline Products & Ongoing Clinical Trials Overview 46
6 Peripheral Embolic Protection Devices- Recent Developments 47
6.1 Jul 05, 2017: Penumbra Promotes Daniel Davis to Chief Commercial Officer 47
6.2 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 47
6.3 Jun 16, 2017: ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome 49
6.4 Jun 16, 2017: Sentinel Cerebral Protection System Used Commercially By TAVR Centers of Excellence Nationwide 50
6.5 Jun 05, 2017: Claret Medical Receives FDA Clearance to Market Sentinel Cerebral Protection System in the U.S. 50
6.6 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 51
6.7 May 22, 2017: OPTALYSE PE Study Demonstrates Safety and Efficacy of Shorter, Lower Dose EKOS Therapy For Pulmonary Embolism 54
6.8 May 09, 2017: Penumbra Reports First Quarter 2017 Financial Results 55
6.9 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 56
6.10 Apr 25, 2017: Edwards Lifesciences Reports First Quarter Results 57
6.11 Apr 21, 2017: Penumbra Appoints Bridget O'Rourke to its Board of Directors 59
6.12 Apr 11, 2017: Testing Device Aimed at Reducing Stroke Risk During Transcatheter Aortic Valve Replacement 59
6.13 Mar 30, 2017: AngioDynamics Reports Fiscal 2017 Third Quarter Results 60
6.14 Mar 30, 2017: MPSC Announces 2016 Annual Results 61
6.15 Mar 21, 2017: Metactive Medical Announces Issuance of Patent on Blockstent Embolization Device 63
6.16 Mar 15, 2017: Innovative Cardiovascular Solutions Announces Successful First Cases in European Clinical Study of EMBLOK Embolic Protection System 64
6.17 Mar 02, 2017: Penumbra Announces Key Events at Society of Interventional Radiology 2017 Meeting 64
6.18 Feb 28, 2017: Penumbra Reports Fourth Quarter and Full Year 2016 Financial Results 65
6.19 Feb 27, 2017: FDA Advisory Committee Strongly Supports Granting de novo Application for the First Cerebral Protection System for Transcatheter Aortic Valve Replacement 67
6.20 Feb 27, 2017: BTG Receives U.S. FDA 510(k) Clearance For EKOS Control Unit 4.0 68
6.21 Feb 27, 2017: Keystone Heart Applauds FDA Advisory Panel for Recognition of The Need for Cerebral Protection Following TAVR 68
6.22 Feb 21, 2017: Medtronic Reports Third Quarter Financial Results 69
6.23 Feb 06, 2017: Medtronic Awarded U.S. Department of Veterans Affairs National Contracts for Home Telehealth Technologies, with Three Other Vendors 72
6.24 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 73
6.25 Feb 01, 2017: Edwards Lifesciences Reports Fourth Quarter Results 74
6.26 Jan 09, 2017: First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS system 76
6.27 Jan 06, 2017: AngioDynamics Reports Fiscal 2017 Second Quarter Results 77
6.28 Dec 19, 2016: Penumbra Appoints Thomas C. Wilder to its Board of Directors 79
6.29 Dec 08, 2016: Edwards Lifesciences Outlines Growth Strategy At Annual Investor Conference 79
6.30 Nov 22, 2016: Medtronic Reports Second Quarter Financial Results 81
6.31 Nov 16, 2016: Medtronic Releases FY16 Integrated Performance Report 84
6.32 Nov 15, 2016: Penumbra Announces Resignation of Board Member 84
6.33 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 85
6.34 Nov 10, 2016: Penumbra to Highlight Peripheral Vascular Technologies at AIMsymposium and VEITHsymposium in New York 86
6.35 Nov 09, 2016: AngioDynamics Announces Addition of New Board Members 87
6.36 Nov 03, 2016: Penumbra Reports Third Quarter 2016 Financial Results 87
6.37 Nov 01, 2016: Results from U.S. Pivotal IDE Trial Show That Sentinel Cerebral Protection System Protects Patients During Transcatheter Aortic Valve Replacement 88
6.38 Nov 01, 2016: Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR According to New Data Released at TCT 2016 90
6.39 Oct 28, 2016: Emboline’s “enabling TAVI” aortic embolic protection technology is selected for presentation at TCT 2016 91
6.40 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 92
6.41 Oct 25, 2016: Edwards Lifesciences Reports Third Quarter Results 93
6.42 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 95
6.43 Oct 05, 2016: AngioDynamics Reports Fiscal 2017 First Quarter Results 96
6.44 Oct 03, 2016: American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR 97
6.45 Sep 20, 2016: Claret Medical Submits Marketing Application to FDA for US Clearance of First Cerebral Protection System for Transcatheter Aortic Valve Replacement (TAVR) 98
6.46 Sep 19, 2016: TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures 99
6.47 Sep 15, 2016: Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services 100
6.48 Sep 14, 2016: Claret Medical Announces SENTINEL Pivotal IDE Trial to Be Featured in Late-Breaking Trial Session at Transcatheter Cardiovascular Therapeutics (TCT) Conference 101
6.49 Aug 30, 2016: MPSC Announces 2016 Interim Results 102
6.50 Aug 25, 2016: Medtronic Reports First Quarter Financial Results 103
6.51 Aug 09, 2016: Penumbra Reports Second Quarter 2016 Financial Results 106
6.52 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 107
6.53 Jul 26, 2016: Edwards Lifesciences Reports Second Quarter Results 109
6.54 Jul 25, 2016: AngioDynamics Appoints Michael C. Greiner as New Chief Financial Officer 110
7 Appendix 112
7.1 Methodology 112
7.2 About GlobalData 115
7.3 Contact Us 115
7.4 Disclaimer 115
1.1 List of Tables
Table 1: Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development 8
Table 2: Peripheral Embolic Protection Devices - Pipeline Products by Segment 9
Table 3: Peripheral Embolic Protection Devices - Pipeline Products by Territory 10
Table 4: Peripheral Embolic Protection Devices - Pipeline Products by Regulatory Path 11
Table 5: Peripheral Embolic Protection Devices - Pipeline Products by Estimated Approval Date 12
Table 6: Peripheral Embolic Protection Devices - Ongoing Clinical Trials 13
Table 7: Peripheral Embolic Protection Devices Companies - Pipeline Products by Stage of Development 14
Table 8: Peripheral Embolic Protection Devices - Pipeline Products by Stage of Development 15
Table 9: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 16
Table 10: Emboshield Pro Rapid Exchange Embolic Protection System (Generation 5) - Product Status 16
Table 11: Emboshield Pro Rapid Exchange Embolic Protection System (Generation 5) - Product Description 16
Table 12: Avantec Vascular Corporation Pipeline Products & Ongoing Clinical Trials Overview 17
Table 13: Peripheral Embolization Device - Product Status 17
Table 14: Peripheral Embolization Device - Product Description 17
Table 15: BTG Plc Pipeline Products & Ongoing Clinical Trials Overview 18
Table 16: EkoSonic Endovascular System - Product Status 18
Table 17: EkoSonic Endovascular System - Product Description 19
Table 18: BTG Plc - Ongoing Clinical Trials Overview 20
Table 19: EkoSonic Endovascular System - Submassive Pulmonary Embolism Experience with EKOS 21
Table 20: Cardio-Flow Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22
Table 21: EmboPRO EPD - Product Status 22
Table 22: EmboPRO EPD - Product Description 22
Table 23: CardioGard Ltd. Pipeline Products & Ongoing Clinical Trials Overview 23
Table 24: CardioGard 22 French Aortic Cannula - Product Status 23
Table 25: CardioGard 22 French Aortic Cannula - Product Description 23
Table 26: CardioGard Ltd. - Ongoing Clinical Trials Overview 24
Table 27: CardioGard 22 French Aortic Cannula - A Study to Collect Additional Information Related to the Performance of the CARDIOGARD Cannula 25
Table 28: EMBA Medical Limited Pipeline Products & Ongoing Clinical Trials Overview 26
Table 29: Hourglass Peripheral Embolization Plug - Product Status 26
Table 30: Hourglass Peripheral Embolization Plug - Product Description 26
Table 31: Emboline, Inc. Pipeline Products & Ongoing Clinical Trials Overview 27
Table 32: Emboliner - Product Status 27
Table 33: Emboliner - Product Description 27
Table 34: Filterlex Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 28
Table 35: Next Generation Embolic Protection Device - Product Status 28
Table 36: Next Generation Embolic Protection Device - Product Description 28
Table 37: Inari Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview 29
Table 38: FlowTriever System - Pulmonary Embolism - Product Status 29
Table 39: FlowTriever System - Pulmonary Embolism - Product Description 29
Table 40: Inari Medical, Inc. - Ongoing Clinical Trials Overview 30
Table 41: FlowTriever System - Pulmonary Embolism - FlowTriever Pulmonary Embolectomy Clinical Study 31
Table 42: Innovative Cardiovascular Solutions, LLC Pipeline Products & Ongoing Clinical Trials Overview 32
Table 43: EMBLOK Embolic Protection System - Product Status 32
Table 44: EMBLOK Embolic Protection System - Product Description 32
Table 45: Innovative Cardiovascular Solutions, LLC - Ongoing Clinical Trials Overview 33
Table 46: EMBLOK Embolic Protection System - European Study Evaluating the EMBLOK Cerebral Embolic Protection System During Transcatheter Aortic Valve Replacement (TAVR) 34
Table 47: EMBLOK Embolic Protection System - Safety and Efficacy of EMBLOK Embolic Protection System in Patients with Severe Aortic Stenosis 34
Table 48: Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 35
Table 49: Permanently Implantable Embolic Balloon - Product Status 35
Table 50: Permanently Implantable Embolic Balloon - Product Description 35
Table 51: Keystone Heart Ltd Pipeline Products & Ongoing Clinical Trials Overview 36
Table 52: TriGuard Cerebral Protection Device - Product Status 36
Table 53: TriGuard Cerebral Protection Device - Product Description 36
Table 54: Keystone Heart Ltd - Ongoing Clinical Trials Overview 37
Table 55: TriGuard Cerebral Protection Device - A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation 38
Table 56: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 39
Table 57: SilverHawk With SpiderFX Embolic Protection Device - Product Status 39
Table 58: SilverHawk With SpiderFX Embolic Protection Device - Product Description 39
Table 59: Metactive Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 40
Table 60: Blockstent Microcatheter - Product Status 40
Table 61: Blockstent Microcatheter - Product Description 40
Table 62: MIV Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 41
Table 63: Aortic Embolic Protection Device - Product Status 41
Table 64: Aortic Embolic Protection Device - Product Description 41
Table 65: Neurosonix Ltd. Pipeline Products & Ongoing Clinical Trials Overview 42
Table 66: Protection Collar - Product Status 42
Table 67: Protection Collar - Product Description 42
Table 68: Shape Memory Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 43
Table 69: Peripheral Vascular Embolization System - Product Status 43
Table 70: Peripheral Vascular Embolization System - Product Description 43
Table 71: Trinity College Dublin Pipeline Products & Ongoing Clinical Trials Overview 44
Table 72: Transcatheter Device - Atherosclerotic Plaque - Product Status 44
Table 73: Transcatheter Device - Atherosclerotic Plaque - Product Description 44
Table 74: University of Minnesota Pipeline Products & Ongoing Clinical Trials Overview 45
Table 75: Embolic Protection Device - Product Status 45
Table 76: Embolic Protection Device - Product Description 45
Table 77: University of Toledo Pipeline Products & Ongoing Clinical Trials Overview 46
Table 78: Minimally Invasive Thrombectomy Device - Product Status 46
Table 79: Minimally Invasive Thrombectomy Device - Product Description 46
Table 80: Glossary 114
